“The acquisition of PreClinOmics will allow CrownBio to create a center of excellence in global translational drug development specifically for cardiovascular and metabolic disease,” said Jean-Pierre Wery, Ph.D., president of Crown Bioscience. “We are confident that the acquisition will ultimately result in greater success in clinical trials and lower the cost of drug development for diseases that produce some of the highest economic costs in the world.”
Friday, 11 March 2016
CROWN BIOSCIENCE ACQUIRES PRECLINOMICS, EXPANDS CARDIOVASCULAR AND METABOLIC DISEASE PORTFOLIO
SANTA CLARA, Calif. March 9 (Bernama-BUSINESS WIRE) -- Crown Bioscience, Inc., a wholly owned subsidiary of Crown Bioscience International (TWSE:ticker 6554), a global drug discovery and development solutions company providing translational platforms to advanceoncology and metabolic disease research, has announced the acquisition of PreClinOmics, Inc., an in vivo preclinical company that specializes in early research in cardiovascular and metabolic diseases (CVMD) as well as renal disease. With this acquisition, CrownBio adds to its portfolio some of the most relevant CVMD models to replicate human disease.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment